عبدالرحمن البرادعي

طبيبٌ، ومحِبٌ للأدبِ قِراءةً و كتابةً وخُلُقا ~

[عبدالرحمن البرادعي @brad3ei]

هل #الحبة السوداء #علاج للأورام؟!

١)

دارَ في خلدي سؤالٌ أشغل تفكيري بعد كثرة السؤال الذي يرِدُني عن الحبة السوداء وعلاجها للأورامِ تحديدا. وكيف نجمع بين حديث الرسول ﷺ الوارد في صحيح البُخاري ( الحَبّةُ السّوداء شفاءٌ من كلِّ داءٍ إلا السَّام )

[Dr Preetam Jain @PreetamJainOnco]

BREAKING NEWS !

Finally... a targeted therapy for HR+/HER2− metastatic breast cancer with PIK3CA wild-type disease.

🧬 Key clinical pearls:

✅ FDA-approved Gedatolisib

✅ After progression on CDK4/6 inhibitor + AI

✅ Triplet PFS: 9.3 vs 2.0 months (HR 0.24)

✅ New option for ~60% of HR+/HER2− MBC patients

Precision oncology continues to evolve.

#ASCO #BreastCancer #MedOnc #MedicalOncology #PrecisionOncology #Gedatolisib #PIK3CA #HRPositive #HER2Negative #MetastaticBreastCancer #TargetedTherapy #Oncology #CancerResearch #DrPreetamJain

@oncodaily @OncoDailyBreast

[Dr Amol Akhade @SuyogCancer]

Excellent slides about definition of endocrine resistance and sequencing of endocrine therapy in 2026. From the talk by @AlexEniu @asco #asco26 🙂👍. Money 💰 Slides .

[Journal of Clinical Oncology @JCO_ASCO]

Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial.

Read the full article. https://t.co/b3K4rL7sIb
#ColorectalCancer #crcsm

[Erman Akkus @Erman_Akkus]

📙Renal and hepatic dose adjustment for oncologists

#cancer #oncology #MedX #drug #treatment #therapy #renal #kidney #hepatic #liver @OncoAlert

[Dr Sarah Sammons @drsarahsam]

Big week for breast cancer at #ASCO26. A few highlights from the meeting:

Metastatic
TROPION-Breast02 + ASCENT-03 (TNBC, PD-L1 ineligible): Two practice-changing Trop2 ADC options for 1L. Subsequent analyses confirm benefit. 2 good options.

VIKTORIA-1 (HR+/HER2-, PIK3CA-mutated, 2L post-CDK4/6i): Gedatolisib + fulvestrant beat alpelisib with a much cleaner toxicity profile. Triplet did not add anything with palbociclib. Less hyperglycemia, less diarrhea. Stomatitis remains a challenge. Will be a nice doublet option if approved. IV drug.

SERENA-6 (HR+/HER2-): Switching to camizestrant when ESR1 mutation is detected on ctDNA, before progression, yielded 51% ctDNA clearance vs 1.9%. Compelling biology. Let’s see what the FDA does.

persevERA (HR+/HER2-, 1L): Giredestrant + palbociclib did not beat letrozole + palbociclib (33.1 vs 28.2 mo, p=0.15). The 1L SERD moment has not arrived yet. Metastatic SERD benefit appears limited to ESR1-mutant disease.

Early Stage
lidERA (HR+/HER2-): First new adjuvant endocrine therapy in decades. Giredestrant cuts recurrence risk about 30% across pre and postmenopausal patients in subgroup analyses. Premenopausal patients need OFS. FDA submission underway.

KEYNOTE-522 at 7 years (TNBC, stage II-III): EFS 78.3% vs 69.8%, OS 85.1% vs 77.2%. The benefit is durable and real. But real-world irAE rates up to 54%. We need a biomarker to identify who can safely skip immunotherapy.

OPTIMA (HR+/HER2-, node-positive): Chemo omission non-inferior in low genomic risk node-positive patients including N2 using Prosigna. Practice changing for postmenopausal patients. For premenopausal, the key insight is that chemo benefit in low genomic risk patients is largely driven by ovarian suppression, not cytotoxicity. Still need more premenopausal N2 data. Enroll to OFSET.

OASIS-4 (HR+, on ET): Elizanetant improves hot flashes AND sleep across tamoxifen, AI, and GnRH agonist therapy. Non-hormonal and safe for HR+ patients. An adherence tool we have really needed.

REDUSE (bone mets): Denosumab every 12 weeks after induction is non-inferior to every 4 weeks for skeletal-related events, with less hypocalcemia, less ONJ, and more than 50% reduction in drug costs. Smarter de-escalation with no efficacy tradeoff.

GLP-1 RAs: Real-world data showing 43% reduction in metastatic progression and 30% mortality reduction in HR+/HER2- patients on ET + CDK4/6i. Still observational, but the tumor GLP-1 receptor expression data suggests this is more than just a metabolic effect. Prospective studies needed.

Grateful for the science.

#BreastCancer #BCSM #Oncology #MedTwitter

[Dr Rishabh Jain @DrRishabhOnco]

🌸 THE 10 MOST IMPORTANT BREAST CANCER TRIALS OF #ASCO26

Chicago is loaded this year.

From ctDNA-guided endocrine switching to frontline ADCs and next-gen HER2 platforms, these are the studies most likely to shape breast oncology practice 👇

🩷 HR+ / HER2- DISEASE

1️⃣ persevERA BC (LBA1006)
Giredestrant + palbociclib vs letrozole + palbociclib in 1L metastatic disease

Despite missing the primary PFS endpoint, biomarker/subset analyses may define where oral SERDs still fit.

2️⃣ SERENA-6 (LBA1007)
Camizestrant for emergent ESR1 mutations detected via ctDNA BEFORE radiographic progression

Possibly the biggest ctDNA-guided endocrine strategy discussion of the meeting.

3️⃣ VIKTORIA-1
Gedatolisib + fulvestrant ± palbociclib after AI + CDK4/6i progression

Huge unmet-need population.
Post-CDK4/6 sequencing remains one of the biggest HR+ questions.

4️⃣ lidERA BC (Abstract 502)
Adjuvant giredestrant in early ER+/HER2- disease

Moving oral SERDs into curative-intent therapy.

5️⃣ FOURLIGHT-2 (Abstract 1042)
Next-gen CDK4-selective inhibition with atirmociclib + letrozole

Can we reduce neutropenia while preserving efficacy?

🔥 TNBC & ADC ERA

6️⃣ ASCENT-04 (LBA1000)
Sacituzumab govitecan + pembrolizumab vs chemo + pembrolizumab in PD-L1+ mTNBC

Could ADC + IO combinations become the frontline standard?

7️⃣ TROPION-Breast02
Dato-DXd vs chemotherapy in metastatic TNBC

A major test of the “ADC-first” paradigm.

🎯 HER2+ & NEXT-GEN NEOADJUVANT PLATFORMS

8️⃣ KN026-004 (LBA660)
Novel biparatopic HER2 antibody vs classic CLEOPATRA-style therapy

Watch the pCR data carefully.

9️⃣ I-SPY 2.2 (LBA514)
Rilvegostomig + T-DXd in high-risk HER2-negative disease

IO + ADC combinations continue moving earlier.

🔟 DESTINY-Breast05 Update
Long-term outcomes for T-DXd vs T-DM1 in residual HER2+ disease

Which breast abstract are you watching most closely?

#BCSM #OncoTwitter #ASCO26 #BreastCancer #MedEd @asco @myesmo @esmo_open @OncoAlert @OncBrothers

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

Your mother was right. Better diet, more exercise, and sunshine are good for you and might even lower breast cancer recurrence! ☀️ 🏃‍♀️ 🥗

[MV Chandrakanth @ChandrakanthMv]

HR+/HER2− breast cancer at #ASCO2026 in one infographic.

This year's story was not about doing more—it was about doing better.

🧬 OPTIMA: genomics-guided chemotherapy de-escalation

💊 lidERA BC: oral SERDs move into early disease

🎯 NATALEE: adjuvant ribociclib benefit across molecular subtypes

🩸 SERENA-6: ctDNA-guided intervention before radiologic progression

⚡ VIKTORIA-1 & INAVO120: expanding options after CDK4/6 inhibitor resistance

⚖️ persevERA BC: a reminder that precision matters more than escalation

The direction is clear: Less chemotherapy. Earlier molecular intervention. More biomarker-driven treatment.

#BreastCancer #HRPositive #Oncology #ASCO #CancerResearch #MVOnco

[Dr Rishabh Jain @DrRishabhOnco]

practice-changing shifts in early breast cancer surgery at #ASCO26.

🧠 Proposed algorithm:
• Age ≥50 + ER+/HER2- + cN0 → omit axillary surgery entirely
• Younger or biologically higher-risk disease → SLNB-guided escalation
• ALND reserved mainly for ≥3 positive nodes

From “maximum surgery” → “minimum necessary surgery.”
QoL is finally driving the conversation too.

@ASCO @OncoAlert @myesmo @esmo_open @larvol #OncoTwitter #BreastCancer

[Oncology Brothers @OncBrothers]

Day 2 #ASCO26 highlights:

Breast Cancer:
1. #KN522 (update): IO + Chemo TNBC

2. #OPTIMA: Adj Chemo HR+

3. #lidERA: Adj SERD HR+

4. #SENOMAC: ALND omission

Prostate Ca
5. #TALAPRO3: PARPi

NSCLC:
6. #TRITON: Dual ICI mNSCLC

#OncTwitter @ASCO @OncoAlert

1/7

[Yakup Ergün @dr_yakupergun]

Current approved treatment options for HR+, HER2− mBC

ESMO Guidelines: Real World Cases Webinar: Metastatic Breast Cancer 2026 presentation

https://t.co/H3S9DZXsK2

[قناة الإخبارية @alekhbariyatv]

نائب المدير التنفيذي للخدمات الطبية بالشؤون الصحية في وزارة الحرس الوطني د. عاصم الصاعدي: الوضع الصحي للحجاج مستقر ولم نرصد أي حالات إجهاد حراري أو ضربات شمس أو ما يستدعي العزل

#الحج_عبر_الإخبارية

[Arndt Vogel @ArndtVogel]

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma
@JHepatology
https://t.co/P7iNmhN87l
👉Disappointing, we need to do better...
@myESMO @EASLedu @ILCAnews

[Mali Barbi, MD MSc | Breast & Gyn Oncologist @DrBarbiOnc]

#HER2+ early #breastcancer just had its biggest two weeks - and #ASCO hasn't even started.
May 15: @FDAOncology approved #TDXd for two indications in early-stage HER2+ disease. Neoadjuvant Stage II–III high-risk: #DB11 ( pCR 67.3% vs 56.3% with ddAC-THP). Anthracyclines, finally challenged. Adjuvant over T-DM1 for residual disease: #DB05 (3-year IDFS 92.4% vs 83.7%, HR 0.47).
T-DXd now owns every line of HER2+ BC. We are deep in the ADC era.
At #ESMOBreast, #SATEEN tested post-T-DXd sequencing. Sacituzumab + trastuzumab in HER2+ mBC after prior T-DXd. Stopped for futility.
>>TROP2-directed topo-1 ADC after HER2-directed topo-1 ADC -provisional answer: no.
>>Which makes #LBA660 at #ASCO26 worth watching critically. #NeoHealer (#KN026_004): #anbenitamab, China-developed HER2 bispecific, no payload, no FDA approval, plus albumin-bound docetaxel vs TCbHP in early/locally advanced HER2+ BC. ~520 pts. Met tpCR endpoint. Full numbers at ASCO for the first time. One molecule. Two non-overlapping HER2 epitopes. Signal blockade, receptor downregulation, enhanced ADCC. No ILD. No ADC toxicity. 6 cycles. Surgery ~6 weeks earlier than T-DXd → THP.
Not the same population. DB11 replaced anthracyclines in high-risk disease. Neo-Healer replaced the dual antibody backbone in broader early/LA disease. Different questions.
Data compelling. Western regulatory path undefined. But the question is sharp: does a payload-free bispecific become the backbone you preserve - precisely to keep T-DXd available for residual disease rescue?
Watch LBA660. Critically.
#ASCO26 #brcsm @ASCO @AlphamabONC

[Erman Akkus @Erman_Akkus]

🟡Transforming perioperative treatment of gastro-oesophageal adenocarcinoma

✅state-of-the-art perioperative management

👉https://t.co/ol258Y3kaR

#cancer #oncology #MedX #gastric @LizzySmyth1 @KoheiShitara @DrHongchengZhu @YJanjigianMD

[MV Chandrakanth @ChandrakanthMv]

What exactly is a Claudin?

Before understanding CLDN18.2 and zolbetuximab in gastric cancer, it helps to understand the biology first.

Claudins are key proteins within epithelial tight junctions.

Their role: • maintain barrier integrity • control movement between cells • preserve epithelial organization

These structures are especially important in: • stomach • intestine • kidney • lung

In gastric cancer, disruption of tight junction architecture can expose CLDN18.2 — creating a therapeutic target.

A simple visual overview.

#MVOnco #GastricCancer #CLDN182 #Zolbetuximab #GIOncology #Oncology #MedEd

[Dr Rishabh Jain @DrRishabhOnco]

🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26

May 29 - June 2 | Chicago
Which trial are you watching most closely?

🌟 PLENARY GAME-CHANGERS

1️⃣ PROTEUS
Perioperative apalutamide + ADT in high-risk localized prostate cancer

2️⃣ LIBRETTO-432
Adjuvant selpercatinib in RET+ NSCLC

3️⃣ HARMONi-6
Ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC

4️⃣ RASolute 302
Daraxonrasib (RMC-6236) in metastatic pancreatic cancer

5️⃣ SARC041
Abemaciclib in dedifferentiated liposarcoma

⚡ FRONTLINE & PERIOPERATIVE SHIFTS

6️⃣ KEYNOTE-B15 / EV-304
EV + pembrolizumab vs chemo in MIBC

7️⃣ LITESPARK-022
Pembrolizumab + belzutifan in adjuvant ccRCC

8️⃣ AMBITION
Paclitaxel/bevacizumab ± atezolizumab in HR+ breast cancer

9️⃣ NeoADAURA
Neoadjuvant osimertinib in EGFR+ NSCLC

�� A-DREAM
ADT interruption strategies in mCSPC

🧬 PRECISION, ADCs & NEXT-GEN IMMUNOLOGY

1️⃣1️⃣ DESTINY-Breast06
T-DXd expands into HER2-ultralow disease

1️⃣2️⃣ CROWN (7-year update)
Lorlatinib durability in ALK+ NSCLC

1️⃣3️⃣ DeLLphi-312
Tarlatamab in frontline SCLC

1️⃣4️⃣ COMMIT
Atezolizumab + FOLFOX/Bev in MSI-H mCRC

1️⃣5️⃣ IMvigor011
ctDNA-guided adjuvant atezolizumab in bladder cancer

#OncoTwitter #MedTwitter #ASCO26 #CancerResearch @OncoAlert @ASCO @JCOPO_ASCO @OncBrothers

[Dr Rupam Manna MD @DrRupamOncology]

🔄 Tamoxifen → Aromatase Inhibitor (AI) switch
& safely stopping Ovarian Function Suppression (OFS)
in HR+ Breast Cancer — hormone levels are your guide.
✅ E2 & FSH thresholds
✅ Natural menopause vs chemo-induced amenorrhea
✅ When you CAN switch to AI alone
✅ When you MUST continue tamoxifen or AI + OFS
✅ Practical ASCO/NCCN algorithm & monitoring tips
📌 Full decision-making infographic 👇
#BreastCancer #Oncology #EndocrineTherapy #HRPositive #CancerEducation
Follow for more visual oncology tools → @DrRupamOncology

[Dr Rupam Manna MD @DrRupamOncology]

📊 GEJ Carcinoma (Gastroesophageal Junction) – Full Guideline-Based Management at a Glance!
Most GEJ adenocarcinomas are treated like esophageal or gastric cancer depending on Siewert type & stage.
This one-pager covers:
• Initial workup & essential biomarkers (HER2, PD-L1 CPS, MSI/dMMR, CLDN18.2, NGS)
• Perioperative FLOT now preferred (superior OS vs CROSS per ESOPEC)
• CROSS as alternative for bulky/borderline disease
• Adjuvant nivolumab (CheckMate-577) after CROSS if residual disease
• Biomarker-driven therapy in metastatic & unresectable settings
• High-yield clinical pearls
Perfect quick reference for fellows, residents & practicing oncologists! 🔖
Save | Share | Tag a colleague
Made with ❤️ by Dr Rupam Manna
Follow for more Cancer Concepts Explained → @DrRupamOncology
#GEJCancer #EsophagealCancer #GastricCancer #Oncology #MedTwitter #CancerGuidelines #FLOT #Immunotherapy

[Dr Rupam Manna MD @DrRupamOncology]

🧬 HER2-Targeted Agents – Mechanism of Action at a Glance!

Trastuzumab • Pertuzumab • Tucatinib • T-DM1 • T-DXd

Crystal-clear breakdown of:
✅ Extracellular blockade (Domain IV & II)
✅ Dimerization blocker
✅ Highly selective TKI with strong CNS penetration
✅ Next-gen ADCs (cleavable linker, high DAR, bystander effect + topoisomerase I inhibition)

Ultra-high-yield comparison table + clinical pearl included 🔥

Perfect quick reference for tumor boards, fellows & exam prep!

Save 🔖 this one & share with your team!

Which HER2 agent is your go-to? Drop it below 👇

#HER2 #BreastCancer #Oncology #ADC #TargetedTherapy #MedEd #CancerEducation

Cancer Concepts Explained by @DrRupamOncology